Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-02-03

FDA Approved: IMODIUM MULTI-SYMPTOM RELIEF — Supplemental Application (Kenvue Brands LLC)

View source ↗

Summary

FDA approved a supplemental application for IMODIUM MULTI-SYMPTOM RELIEF (loperamide HCl and dimethicone) from Kenvue Brands LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)

Snippet

SUPPL AP for IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)